Skip to main content
main-content

01.12.2017 | Research article | Ausgabe 1/2017 Open Access

BMC Health Services Research 1/2017

A comparison of generic drug prices in seven European countries: a methodological analysis

Zeitschrift:
BMC Health Services Research > Ausgabe 1/2017
Autoren:
Olivier J. Wouters, Panos G. Kanavos
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​s12913-017-2184-5) contains supplementary material, which is available to authorized users.

Abstract

Background

Policymakers and researchers frequently compare the prices of medicines between countries. Such comparisons often serve as barometers of how pricing and reimbursement policies are performing. The aim of this study was to examine methodological challenges to comparing generic drug prices.

Methods

We calculated all commonly used price indices based on 2013 IMS Health data on sales of 3156 generic drugs in seven European countries.

Results

There were large differences in generic drug prices between countries. However, the results varied depending on the choice of index, base country, unit of volume, method of currency conversion, and therapeutic category. The results also differed depending on whether one looked at the prices charged by manufacturers or those charged by pharmacists.

Conclusions

Price indices are a useful statistical approach for comparing drug prices across countries, but researchers and policymakers should interpret price indices with caution given their limitations. Price-index results are highly sensitive to the choice of method and sample. More research is needed to determine the drivers of price differences between countries. The data suggest that some governments should aim to reduce distribution costs for generic drugs.
Zusatzmaterial
Additional file 1: Appendix 1. List of the 200 most-prescribed off-patent active ingredients in Europe in 2013 (anatomical main group in parentheses). Appendix 2. Ex-manufacturer and retail prices with France as the base country (2013). Appendix 3. Ex-manufacturer and retail prices based on PPP adjustments with Germany as the base country (2013). Appendix 4. Ex-manufacturer and retail prices of cardiovascular and nervous system drugs with Germany as the base country (2013). (DOCX 58 kb)
12913_2017_2184_MOESM1_ESM.docx
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2017

BMC Health Services Research 1/2017 Zur Ausgabe